Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Biological products | 1 |
Top 5 Target | Count |
---|---|
SARS-CoV-2 S protein(SARS-CoV-2 S protein) | 1 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Apoptosis stimulants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2023 |
Sponsor / Collaborator |
Start Date01 May 2023 |
Sponsor / Collaborator |
Start Date01 Dec 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
UT28K ( SARS-CoV-2 S protein ) | Coronavirus Infections More | Preclinical |
Arctigenin | Pancreatic Cancer More | Pending |